132 related articles for article (PubMed ID: 10706711)
1. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes.
Giovarelli M; Cappello P; Forni G; Salcedo T; Moore PA; LeFleur DW; Nardelli B; Di Carlo E; Lollini PL; Ruben S; Ullrich S; Garotta G; Musiani P
J Immunol; 2000 Mar; 164(6):3200-6. PubMed ID: 10706711
[TBL] [Abstract][Full Text] [Related]
2. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.
Giovarelli M; Musiani P; Modesti A; Dellabona P; Casorati G; Allione A; Consalvo M; Cavallo F; di Pierro F; De Giovanni C
J Immunol; 1995 Sep; 155(6):3112-23. PubMed ID: 7673726
[TBL] [Abstract][Full Text] [Related]
3. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
[TBL] [Abstract][Full Text] [Related]
4. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
[TBL] [Abstract][Full Text] [Related]
5. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor.
Guiducci C; Di Carlo E; Parenza M; Hitt M; Giovarelli M; Musiani P; Colombo MP
J Immunol; 2004 Apr; 172(7):4026-36. PubMed ID: 15034014
[TBL] [Abstract][Full Text] [Related]
6. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.
Cavallo F; Signorelli P; Giovarelli M; Musiani P; Modesti A; Brunda MJ; Colombo MP; Forni G
J Natl Cancer Inst; 1997 Jul; 89(14):1049-58. PubMed ID: 9230887
[TBL] [Abstract][Full Text] [Related]
8. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.
Cavallo F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Modesti A; Forni G
J Immunol; 1992 Dec; 149(11):3627-35. PubMed ID: 1358974
[TBL] [Abstract][Full Text] [Related]
9. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
10. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory.
Consalvo M; Mullen CA; Modesti A; Musiani P; Allione A; Cavallo F; Giovarelli M; Forni G
J Immunol; 1995 May; 154(10):5302-12. PubMed ID: 7730633
[TBL] [Abstract][Full Text] [Related]
11. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway.
Di Carlo E; Cappello P; Sorrentino C; D'Antuono T; Pellicciotta A; Giovarelli M; Forni G; Musiani P; Triebel F
J Pathol; 2005 Jan; 205(1):82-91. PubMed ID: 15586367
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
[TBL] [Abstract][Full Text] [Related]
14. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
Di Carlo E; Coletti A; Modesti A; Giovarelli M; Forni G; Musiani P
Eur Cytokine Netw; 1998 Mar; 9(1):61-8. PubMed ID: 9613679
[TBL] [Abstract][Full Text] [Related]
15. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement.
Di Carlo E; Comes A; Basso S; De Ambrosis A; Meazza R; Musiani P; Moelling K; Albini A; Ferrini S
J Immunol; 2000 Sep; 165(6):3111-8. PubMed ID: 10975824
[TBL] [Abstract][Full Text] [Related]
16. The immune response elicited by mammary adenocarcinoma cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells.
Nanni P; De Giovanni C; Nicoletti G; Landuzzi L; Rossi I; Frabetti F; Giovarelli M; Forni G; Cavallo F; Di Carlo E; Musiani P; Lollini PL
Hum Gene Ther; 1998 Jan; 9(2):217-24. PubMed ID: 9472781
[TBL] [Abstract][Full Text] [Related]
17. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
[TBL] [Abstract][Full Text] [Related]
18. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells.
Braun SE; Chen K; Foster RG; Kim CH; Hromas R; Kaplan MH; Broxmeyer HE; Cornetta K
J Immunol; 2000 Apr; 164(8):4025-31. PubMed ID: 10754294
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
20. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P
Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
